<div id="readability-page-1"><div>(TheNewswire)<ul><ul></ul></ul>Vancouver, British Columbia –TheNewswire - February 18, 2026 – MindBio Therapeutics Corp. (Frankfurt: WF6) (OTCQB: MBQIF) (“MindBio” or the “Company”), a biotechnology companycommercializing AI-driven voice analytics for drug and alcoholintoxication detection, today announced it has commenced developmentof a proprietary edge computing platform, including dedicatedhardware, to enable large-scale deployment in the miningindustry.The Company is working with an experienced engineeringfirm with expertise in hardware and sensor development to design andmanufacture the Company’s integrated Edge AI solution for real-time,on-device voice analysis in remote and infrastructure-limitedenvironments. Prototype development is nearing completion, withhardware manufacturing and field-ready deployment expected in Q22026.The MindBio hardware device will be sold direct and viadistribution channels. Every device will also have a recurring revenuestream for use of the installed software - the Voice AI intoxicationdetection models developed by MindBio.MindBio is actively pursuing enterprise-levelcommercialization opportunities, with its first targeted deploymentfocused on the mining sector. The Company has initiated operations inSouth America and deployed engineering personnel to supportdevelopment of an industry-specific testing protocol. MindBio isworking with mining operators and health authorities in Chile to alignits technology with existing regulatory frameworks, wheregovernment-mandated drug and alcohol testing is in place.Upon completion, the Edge AI platform is expected tosupport scalable deployment across additional safety-criticalindustries, including aviation and heavy industrial sectors, wherezero-tolerance policies exist but current testing methods areinvasive, episodic, and costly.Workforce studies in Chile indicate alcohol consumptionamong mining workers exceeds 75%, with more than 40% classified asproblem drinkers and approximately 9% reporting drug use across aworkforce of more than 200,000 individuals (ACHS, 2012; SENDA, 2024).Internationally, 20–25% of occupational accidents are estimated tobe directly or indirectly linked to substance use (InternationalLabour Organization, 1996; 2022; Gomez et al., 2002). These dataunderscore a significant global market opportunity for scalable,non-invasive intoxication detection technologies.Justin Hanka, CEO of MindBio, commented:“MindBio is leveraging its first-mover position in AI-powered voicediagnostics to develop scalable workplace health and safety solutionsaddressing drug and alcohol impairment. We are encouraged by earlyindustry engagement and look forward to initial deployment inChile’s mining sector, followed by broader expansion across SouthAmerica and other global markets.”For further information, please contact:Justin Hanka, Chief ExecutiveOfficer+61 433140886justin@mindbiotherapeutics.comwww.mindbiotherapeutics.comAbout MindBio TherapeuticsCorp.MindBio is a biotechnologycompany that is commercialising AI prediction technologies for drugand alcohol intoxication detection via voice analysis. The AIprediction model uses over 50 million data points to predict alcoholintoxication with remarkable accuracy, just by using the human voice.The Company is now collecting data that will allow its prediction toolto work on other types of intoxication for use in consumer andenterprise environments.Cautionary Note ConcerningForward-Looking Statements: The press release contains “forward-lookingstatements” within the meaning of applicable securities laws,including but not limited to, the Company’s ability to complete theOffering and option grants on the terms announced, and the developmentof its enterprise platform using voice and powered by AI for use indetecting drug and alcohol intoxication. Forward-looking statementscan be identified by words such as: “anticipate,” “intend,”“plan,” “budget,” “believe,” “project,”“estimate,” “expect,” “scheduled,” “forecast,”“strategy,” “future,” “likely,” “may,” “to be,”“could,” “would,” “should,” “will” and similarreferences to future periods or the negative or comparableterminology, as well as terms usually used in the future andconditional. Forward-looking statements are based on assumptions as ofthe date they are provided. However, there can be no assurance thatsuch assumptions will reflect the actual outcome of such items orfactors. Additionally, there are known and unknown risk factorsthat could cause the Company’s actual results and financialconditions to differ materially from those indicated in theforward-looking statements. Therefore, you should not rely on any ofthese forward-looking statements. Important risk factors that couldcause actual results and financial conditions to differ materiallyfrom those indicated in the forward-looking statements, include amongothers: the risk that the Company may not be able to raise the grossproceeds of the Offering; the failure to obtain the final regulatoryapproval; and technical challenges in the development or deployment ofits enterprise platform; general economic,market and business conditions in Canada and Australia; marketvolatility; and unforeseen delays in timelines for any of thetransactions or events described in this press release. Allforward-looking information is qualified in its entirety by thiscautionary statement. The Company disclaims any obligation to revise orupdate any such forward-looking statement or to publicly announce theresult of any revisions to any of the forward-looking informationcontained herein to reflect future results, events or developments,except as required by law.Neither the Canadian Securities Exchange nor itsRegulation Service Provider (as that term is defined in the policiesof the Canadian Securities Exchange) accepts responsibility for theadequacy or accuracy of of the information in this pressrelease.Copyright (c) 2026 TheNewswire - All rights reserved.</div></div>

BTAI

SBIO

MindBio Therapeutics Corp. has announced the development of a proprietary edge computing platform for large-scale deployment of AI-driven voice analytics for drug and alcohol intoxication detection, targeting the mining industry. The company is collaborating with an engineering firm to create a hardware solution for real-time voice analysis. Initial deployment is planned in Chile, with potential expansion into other safety-critical sectors. The technology aims to address high rates of substance use in mining, presenting a significant market opportunity for non-invasive detection methods. CEO Justin Hanka emphasized the company's first-mover advantage in this field.

The newswire.ca

Bioxcel Therap

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Mustang Bio

PASITHEA THERAPEUTICS CORP C/WTS 12/08/2026 (TO PUR COM)

SPDR S&P Biotech

ESC NEUBASE THERAPEUTI

iShares US Pharma

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VG Health

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Pasithea Therapeutics

Invesco Nasdaq Biotechnology ETF

biote Corp.

Ark Genomic Revolution ETF

MindBio Advances Large-Scale Deployment of Voice Intoxication Detection Through Integrated Edge AI Hardware-Software Platform